瑞替普酶与重组链激酶治疗急性心肌梗死的疗效和安全性比较  

Efficacy and safety comparison of reteplase and recombinant streptokinase in patients with acute myocardial infarction

作　　者：高艳艳[1] 

机构地区：[1]沈丘县中医院,河南沈丘466300

出　　处：《基层医学论坛》2014年第14期1769-1771,共3页The Medical Forum

摘　　要：目的观察比较瑞替普酶与重组链激酶治疗急性心肌梗死的疗效和安全性。方法将133例急性心肌梗死患者随机分为瑞替普酶治疗组(66例)和重组链激酶治疗组(67例),分别对2组患者的血管再通率、住院期间再梗死、梗死后心绞痛、恶性心律失常、KillipⅢ级以上心功能、心源性休克、低血压发生率及30 d病死率和出血副反应进行比较。结果溶栓后梗死相关血管再通率瑞替普酶组明显高于重组链激酶组(P<0.05),2组再梗死﹑梗死后心绞痛﹑心律失常、心力衰竭、心源性休克、低血压发生率及30 d病死率无显著性差异(P>0.05)。结论瑞替普酶用于急性心肌梗死的静脉溶栓治疗,其血管再通率显著高于重组链激酶。Objective To evaluate the efficacy and safety of thrombolytic therapy with reteplase and recombinant streptokinase （r -SK ） in patients with acute myocardial infarction （AMI）.Methods One hundred and thirty -three patients with AMI were randomly divided into reteplase therapy group （66 cases ） and recombinant streptokinase therapy group （67 cases ）.Their reperfusion rate, re -infarction,post -infarction angina, severe arrthymia, heart failure, cardiogenic shock, hypotension, the 30 day mortality rate and hemorrhage side effect were analysed respectively. Results The reperfusian rate of reteplase group after thrombolysis was significantly higher than r -SK group （P〈0.05）.There were no significant differences of re -infarction,post -infarction angina, severe arrthymia,heart failure,cardiogenic shock,hypotension and 30 day mortality rate between the two groups （P〉0.05）.Conclusion The reperfusion rate is significantly higher with intravenous reteplase thrombolytic therapy than r -SK in patients with AMI.

关 键 词：急性心肌梗死 溶栓治疗 瑞替普酶 重组链激酶 

分 类 号：R542.22[医药卫生—心血管疾病]